Knockdown of CMTM6 resulted in decreased PD-L1 expression and increased tumor-infiltrating CD4+CD8+ T cells (Tregs), which consequently improved antitumor immunity and cisplatin-induced apoptosis; whereas overexpression of CMTM6 resulted in increased PD-L1 expression and decreased sensitivity of OSCC cells to cisplatin (95, 96). The gene discussed is CMTM6; the disease is neoplasm.